<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03830255</url>
  </required_header>
  <id_info>
    <org_study_id>FWA000017585</org_study_id>
    <nct_id>NCT03830255</nct_id>
  </id_info>
  <brief_title>Effect of Genetic Polymorphism on Calcineurin Inhibitors Levels in Egyptian Renal Transplant Patients</brief_title>
  <official_title>Calcineurin Inhibitors Among Egyptian Renal Transplant Patients: a Pharmacognetic Based Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helwan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Helwan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Renal transplantation is the treatment of choice for patients with end-stage renal disease&#xD;
      (ESRD). Calcineurin Inhibitors tacrolimus and cyclosporine are the principle&#xD;
      immunosuppressive agents administered to solid organ transplant recipients to prevent and&#xD;
      treat allograft rejection.&#xD;
&#xD;
      The aim of the present study is to detect the incidence of some selected genetic polymorphism&#xD;
      in Egyptian renal transplant population and investigate the influence of these genetic&#xD;
      polymorphism (SNPs )on Cyclosporine and Tacrolimus blood concentration. In addition to detect&#xD;
      the association between these genetic polymorphism variants and patients' clinical outcome&#xD;
      after transplantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tacrolimus and cyclosporine are the principle immunosuppressive agents administered to solid&#xD;
      organ transplant recipients to prevent and treat allograft rejection.They both exert their&#xD;
      immunosppressive action by inhibiting the calcinurein in T-lymphoctes.&#xD;
      Subsequently,Cyclosporin and tacrolimus are both metabolic substrates for cytochrome P450&#xD;
      (CYP) 3A enzymes - in particular, CYP3A4 and CYP3A5 - and are transported out of cells by the&#xD;
      P-glycoprotein (ABCB1) efflux pump. Different expression of CYP3A4, CYP3A5 and P-glycoprotein&#xD;
      causes patient to-patient variability in the absorption, metabolism and tissue distribution&#xD;
      of calcineurin inhibitors. This different expression is likely to be at least partially the&#xD;
      result of mutations in the genes encoding for these enzymes and drug transporter. This may&#xD;
      lead to variable drug concentrations within the systemic circulation and at target sites,&#xD;
      influencing drug efficacy. Moreover, it will influence the individual's susceptibility to&#xD;
      drug interactions and drug toxicity&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Actual">March 29, 2020</completion_date>
  <primary_completion_date type="Actual">October 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>CYP enzymes genetic polymorphism and calcineurin inhibitors drug levels</measure>
    <time_frame>3 months</time_frame>
    <description>Association of CP3A4 and CYP3A5 genetic polymorphism SNPs on Cyclosporine and Tacrolimus blood concentration</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">143</enrollment>
  <condition>Renal Transplantation</condition>
  <arm_group>
    <arm_group_label>Renal Transplant patients treated with cyclosporine</arm_group_label>
    <description>Detecting the genetic polymorphism affecting cyclosporine level</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Renal Transplant patients treated with tacrolimus</arm_group_label>
    <description>Detecting the genetic polymorphism affecting tacrolimus level</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Peripheral blood samples will be collected and stored in - 80°C environment for DNA&#xD;
      extraction by DNA extraction kit according to manufacturer recommendation&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Renal Transplant Patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Kidney transplant patients.&#xD;
&#xD;
          2. Treatment with calcineurin inhibitors (CNI) either Cyclosporine (Neoral®) or&#xD;
             Tacrolimus (Prograf®).&#xD;
&#xD;
          3. Absence of medication known to interact with CNI&#xD;
&#xD;
          4. Age18 years and more&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient who experience acute rejection, graft failure.&#xD;
&#xD;
          2. Medications that interact with Calcineurin Inhibitors.&#xD;
&#xD;
          3. Pregnant or nursing women.&#xD;
&#xD;
          4. Patients who decline to participate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Magdy El Sharkawy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ain Shams University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abdel hameed Ibrahim Mohamed Ebid, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Helwan University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Neama Lotfy, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ain sham university</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohamed Adel, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Helwan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ain shams university specialized hospital</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 1, 2019</study_first_submitted>
  <study_first_submitted_qc>February 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2019</study_first_posted>
  <last_update_submitted>March 25, 2021</last_update_submitted>
  <last_update_submitted_qc>March 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Misr International University</investigator_affiliation>
    <investigator_full_name>Dina Ahmed Mohamed Ali Ismail</investigator_full_name>
    <investigator_title>Lecturer Assistant at Clinical Pharmacy and Pharmacy Practice department</investigator_title>
  </responsible_party>
  <keyword>Renal Transplantation</keyword>
  <keyword>Genetic Polymorphism</keyword>
  <keyword>CYP3A5</keyword>
  <keyword>CYP3A4</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

